CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
393
Frequently Asked Questions
What is Market Cap of CRISPR Therapeutics AG?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. CRISPR Therapeutics AG market cap is $5.26B.
What is the 52-week high for CRISPR Therapeutics AG?
52 week high is the highest price of a stock in the past 52 weeks, or one year. CRISPR Therapeutics AG 52 week high is $71.13 as of September 16, 2025.
What is the 52-week low for CRISPR Therapeutics AG?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. CRISPR Therapeutics AG 52 week low is $30.04 as of September 16, 2025.
What is CRISPR Therapeutics AG stock price today?
CRISPR Therapeutics AG stock price today is $61.19.
What was CRISPR Therapeutics AG stock price yesterday?
CRISPR Therapeutics AG stock price yesterday was $57.84.
What is the PE ratio of CRISPR Therapeutics AG?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. CRISPR Therapeutics AG’s P/E ratio is -10.67.
What is the Price-to-Book ratio of CRISPR Therapeutics AG?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. CRISPR Therapeutics AG P/B ratio is 2.9873.
What is the 50-day moving average of CRISPR Therapeutics AG?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. CRISPR Therapeutics AG 50-day moving average is $56.84.
How many employess does CRISPR Therapeutics AG has?
CRSP CRISPR Therapeutics AG